세계의 캐리어 스크리닝 시장(-2028년) : 제품 및 서비스별, 유형별(확대(맞춤형, 사전설계), 대상 질환), 질환별(혈액, 폐), 기술별(DNA 시퀀싱, PCR), 최종사용자별, 지역별

Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases), Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028

US $ 4,950 ￦ 6,907,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,279,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,372,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,954,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 개요

세계 캐리어 스크리닝 시장 규모는 2023년 22억 달러에서 예측 기간 동안 19.7%의 CAGR을 기록하며 2028년에는 54억 달러 규모로 성장할 것으로 예상됩니다.

시장을 이끄는 요인으로는 차세대 염기서열 분석(NGS)과 같은 유전자 검사 기술의 지속적인 발전으로 인해 캐리어 스크리닝의 효율성, 정확성 및 비용 효율성이 향상되고, 유전성 질환의 유병률이 증가함에 따라 다양한 질환의 유전적 기반에 대한 이해도가 높아진 점 등이 있습니다.

조사 범위
조사 대상 연도	2021-2028년
기준 연도	2022년
예측 기간	2023-2028년
단위	금액(달러)
부문	제품 및 서비스별, 유형별, 질환별, 기술별, 최종사용자별, 지역별
대상 지역	북미(미국, 캐나다), 유럽(독일, 프랑스, 영국, 스페인, 이탈리아, 기타), 아시아태평양(중국, 인도, 일본, 기타), 기타 지역(라틴아메리카, 중동 및 아프리카, GCC 국가)

질환별로는 신경질환 부문이 예측 기간 동안 두 번째로 큰 비중을 차지할 것으로 예상됩니다. 헌팅턴병, 근위축성 측삭경화증(ALS), 간질과 같은 질환의 유전적 기초를 이해하는 것은 이러한 질환이 미래 세대에 전달될 위험을 평가하는 데 매우 중요합니다. 마찬가지로, 신경질환의 보균자 선별검사는 유전적 위험 요인을 조기에 발견할 수 있게 해줍니다. 조기 보인자 확인은 개인이나 부부가 충분한 정보를 바탕으로 생식 결정을 내릴 수 있는 기회를 제공하고, 계획 단계 초기에 개입과 치료를 고려할 수 있는 기회를 제공합니다.

기술별로는 PCR 기술 부문이 두 번째로 높은 점유율을 보이고 있으며, PCR 기술은 특정 DNA 염기서열을 증폭하고 검출하는 데 있어 높은 민감도와 특이성을 가지고 있는 것으로 알려져 있습니다. 이러한 정확성은 다양한 질병과 관련된 유전자 돌연변이의 보균자를 확실하게 식별하기 위한 캐리어 스크리닝에 있어 매우 중요합니다. 마찬가지로, PCR은 한 번의 반응으로 여러 개의 표적 DNA 서열을 증폭할 수 있는 다중화(multiplexing) 기능을 제공합니다. 이 기능은 캐리어 스크리닝에 매우 유용합니다.

세계의 캐리어 스크리닝 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 환경, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 동향
• 가격 분석
• 밸류체인 분석
• 공급망 분석
• Porter's Five Forces 분석
• 생태계/시장 맵
• 관세와 규제 상황
• 특허 분석
• 고객의 비지니스에 영향을 미치는 동향/디스럽션
• 주요 회의와 이벤트
• 기술 분석
• 주요 이해관계자와 구입 기준
• 무역 분석

제6장 캐리어 스크리닝 시장 : 제품 및 서비스별

• 서비스
• 제품

제7장 캐리어 스크리닝 시장 : 유형별

• 확대형 캐리어 스크리닝
  • 사전설계 패널 테스트
  • 맞춤형 패널 테스트
• 표적 질환 캐리어 스크리닝

제8장 캐리어 스크리닝 시장 : 질환별

• 폐질환
• 혈액질환
• 신경질환
• 기타

제9장 캐리어 스크리닝 시장 : 기술별

• DNA 시퀀싱
• PCR
• DNA 마이크로어레이
• 기타

제10장 캐리어 스크리닝 시장 : 최종사용자별

• 병원·의료 센터
• 임상 실험실
• 불임 클리닉
• 기타

제11장 캐리어 스크리닝 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 기타 지역

제12장 경쟁 상황

• 개요
• 주요 전략/유력 기업
• 시장 점유율 분석
• 매출 점유율 분석
• 기업 평가 매트릭스
• 스타트업/중소기업 평가 매트릭스
• 경쟁 시나리오와 동향

제13장 기업 개요

• 주요 기업
  • NATERA, INC.
  • QUEST DIAGNOSTICS INCORPORATED
  • FULGENT GENETICS
  • INVITAE CORPORATION
  • EUROFINS SCIENTIFIC
  • OPKO HEALTH, INC.
  • THERMO FISHER SCIENTIFIC INC.
  • MYRIAD GENETICS, INC.
  • ILLUMINA, INC.
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • CENTOGENE N.V.
  • DIASORIN S.P.A.
  • BGI
  • OTOGENETICS
  • GENETECH
• 기타 기업
  • OXY-GEN LABORATORY LLC
  • MEDGENOME
  • AMBRY GENETICS.
  • ASPER BIOGENE
  • LIFELABS GENETICS
  • EASYDNA
  • LIFECELL
  • CNC PATH LAB
  • SIGNATURE DIAGNOSTICS INC.
  • MITERA

제14장 부록

ksm

영문 목차

영문목차

Report Description

The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period. Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.

Scope of the Report
Years Considered for the Study	2021-2028
Base Year	2022
Forecast Period	2023-2028
Units Considered	Value (USD) Billion
Segments	Product & Service, Type, Medical Condition, Technology, End User, and Region
Regions covered	North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America, Middle East & Africa, GCC countries)

"The Neurological Conditions accounted for the second largest market share in the carrier screening market product' s market, during the forecast period"

Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.

"PCR technology segment accounted for the second largest market share"

Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,

"APAC region accounted for the third highest CAGR"

The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.

"Europe is estimated to register the second highest CAGR during the forecast period."

In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

Invitae Corporation. (US)

Fulgent Genetics.(US)

Eurofins Scientific (Germany)

OPKO Health, Inc.(US)

Thermo Fisher Scientific Inc.(US)

Quest Diagnostics Incorporated (US)

Myriad Genetics, Inc (US)

Illumina, Inc.(US)

Natera, Inc.(Italy)

Laboratory Corporation of America Holdings.(US)

CENTOGENE N.V.(Germany)

DiaSorin S.p.A.(Italy)

BGI (China)

Otogenetics (US)

GeneTech (India)

Signature Diagnostics Inc.(US)

MedGenome (US)

Ambry Genetics.(US)

Asper Biogene (Estonia)

LifeLabs Genetics (Canada)

EasyDNA (US)

LifeCell (India)

CNC Path Lab (India)

Oxy-Gen Laboratory LLC (US)

Mitera (US)

Research Coverage:

This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.

Market Penetration: Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market

Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 MARKET SCOPE
  • 1.4.1 MARKETS COVERED
  • 1.4.2 REGIONS COVERED
  • 1.4.3 YEARS CONSIDERED
  • 1.4.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
  • 1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • FIGURE 2 KEY SECONDARY SOURCES
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 PRIMARY SOURCES
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primary interviews
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.2 MARKET ESTIMATION
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 7 MARKET SIZE ESTIMATION: CARRIER SCREENING MARKET
  • 2.2.2 GROWTH FORECAST
  • FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
• 2.4 RESEARCH LIMITATIONS
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 RISK ASSESSMENT
  • TABLE 1 RISK ASSESSMENT: CARRIER SCREENING MARKET
• 2.8 IMPACT OF ECONOMIC RECESSION ON CARRIER SCREENING MARKET

3 EXECUTIVE SUMMARY

• FIGURE 11 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
• FIGURE 12 CARRIER SCREENING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
• FIGURE 13 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2023 VS. 2028 (USD MILLION)
• FIGURE 14 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
• FIGURE 15 CARRIER SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 16 CARRIER SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 CARRIER SCREENING MARKET OVERVIEW
  • FIGURE 17 GROWING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET
• 4.2 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023-2028
  • FIGURE 18 PREDESIGNED PANEL TESTING SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• 4.3 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2023
  • FIGURE 19 US AND PRODUCTS TO DOMINATE NORTH AMERICAN CARRIER SCREENING MARKET IN 2023
• 4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: CARRIER SCREENING MARKET
  • FIGURE 20 US TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: CARRIER SCREENING MARKET
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing emphasis on early disease detection and prevention
    • 5.2.1.2 Growing prevalence of genetic disorders
    • 5.2.1.3 High risk of chromosomal abnormalities with advancing maternal age
  • TABLE 2 GLOBAL INCIDENCE RATE OF TRISOMY
    • 5.2.1.4 Increased focus on preconception and prenatal testing
    • 5.2.1.5 Rising number of fertility clinics and IVF centers
    • 5.2.1.6 Declining rate of fertility
  • TABLE 3 FERTILITY RATE (BIRTHS PER WOMAN), BY COUNTRY
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Ethical concerns in preconception genetic carrier screening
    • 5.2.2.2 High cost of carrier screening
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increased awareness about reproductive health in emerging economies
  • FIGURE 22 HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012-2020
    • 5.2.3.2 Integration with telehealth and digital health platforms
    • 5.2.3.3 Increased number of collaborations and partnerships among healthcare organizations
    • 5.2.3.4 Increasing number of government initiatives and policies toward genetic health improvement
    • 5.2.3.5 Growing focus on health screening for rare diseases
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of skilled professionals
    • 5.2.4.2 Lack of standard guidelines for carrier screening
• 5.3 TRENDS
  • 5.3.1 LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING
• 5.4 PRICING ANALYSIS
  • TABLE 4 INDICATIVE PRICING OF CARRIER SCREENING PRODUCTS/SERVICES
  • TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 24 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 PORTER'S FIVE FORCES: CARRIER SCREENING MARKET
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 ECOSYSTEM/MARKET MAP
  • FIGURE 25 ECOSYSTEM/MARKET MAP: CARRIER SCREENING MARKET
  • TABLE 7 ROLE IN ECOSYSTEM: CARRIER SCREENING MARKET
  • FIGURE 26 KEY PLAYERS IN CARRIER SCREENING MARKET
• 5.9 TARIFF & REGULATORY LANDSCAPE
  • TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CARRIER SCREENING MARKET
  • 5.9.1 NORTH AMERICA
    • 5.9.1.1 US
    • 5.9.1.2 Canada
  • 5.9.2 EUROPE
    • 5.9.2.1 UK
    • 5.9.2.2 France
  • 5.9.3 ASIA PACIFIC
    • 5.9.3.1 Japan
    • 5.9.3.2 India
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT TRENDS FOR CARRIER SCREENING
  • FIGURE 27 PATENT TRENDS FOR CARRIER SCREENING, JANUARY 2013-DECEMBER 2023
  • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • FIGURE 28 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CARRIER SCREENING PATENTS, JANUARY 2013- DECEMBER 2023
• 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.11.1 REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS
  • FIGURE 29 REVENUE SHIFT FOR CARRIER SCREENING PRODUCTS/SERVICES
• 5.12 KEY CONFERENCES & EVENTS
  • TABLE 9 DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
• 5.13 TECHNOLOGY ANALYSIS
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS
  • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS
  • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS (%)
  • 5.14.2 BUYING CRITERIA
  • FIGURE 31 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
  • TABLE 11 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
• 5.15 TRADE ANALYSIS
  • TABLE 12 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)

6 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 14 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 SERVICES
  • 6.2.1 RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET
  • TABLE 15 CARRIER SCREENING MARKET FOR SERVICES, BY REGION, 2021-2028 (USD MILLION)
• 6.3 PRODUCTS
  • 6.3.1 GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET
  • TABLE 16 KEY PLAYERS PROVIDING CARRIER SCREENING PRODUCTS
  • TABLE 17 CARRIER SCREENING MARKET FOR PRODUCTS, BY REGION, 2021-2028 (USD MILLION)

7 CARRIER SCREENING MARKET, BY TYPE

• 7.1 INTRODUCTION
  • TABLE 18 CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
• 7.2 EXPANDED CARRIER SCREENING
  • TABLE 19 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 20 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)
  • 7.2.1 PREDESIGNED PANEL TESTING
    • 7.2.1.1 Predesigned panel testing segment to command larger market share during forecast period
  • TABLE 21 PREDESIGNED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.2.2 CUSTOMIZED PANEL TESTING
    • 7.2.2.1 Better customization options for meeting specific customer requirements to drive segment
  • TABLE 22 CUSTOMIZED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
• 7.3 TARGETED DISEASE CARRIER SCREENING
  • 7.3.1 INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET
  • TABLE 23 CARRIER SCREENING MARKET FOR TARGETED DISEASE CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)

8 CARRIER SCREENING MARKET, BY MEDICAL CONDITION

• 8.1 INTRODUCTION
  • TABLE 24 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
• 8.2 PULMONARY CONDITIONS
  • 8.2.1 INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET
  • TABLE 25 LIVE BIRTH INCIDENCE OF CYSTIC FIBROSIS
  • TABLE 26 CARRIER SCREENING PRODUCTS/SERVICES FOR CYSTIC FIBROSIS
  • TABLE 27 CARRIER SCREENING MARKET FOR PULMONARY CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
• 8.3 HEMATOLOGICAL CONDITIONS
  • 8.3.1 RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET
  • TABLE 28 CARRIER SCREENING MARKET FOR HEMATOLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
• 8.4 NEUROLOGICAL CONDITIONS
  • 8.4.1 INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET
  • TABLE 29 GLOBAL PREVALENCE OF NEUROLOGICAL CONDITIONS
  • TABLE 30 CARRIER SCREENING PRODUCTS/SERVICES FOR NEUROLOGICAL CONDITIONS
  • TABLE 31 CARRIER SCREENING MARKET FOR NEUROLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
• 8.5 OTHER MEDICAL CONDITIONS
  • TABLE 32 CARRIER SCREENING MARKET FOR OTHER MEDICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)

9 CARRIER SCREENING MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
  • TABLE 33 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 9.2 DNA SEQUENCING
  • 9.2.1 DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
  • TABLE 34 DNA SEQUENCING USED BY MARKET PLAYERS
  • TABLE 35 CARRIER SCREENING MARKET FOR DNA SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
• 9.3 PCR
  • 9.3.1 HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET
  • TABLE 36 PCR USED BY MARKET PLAYERS
  • TABLE 37 CARRIER SCREENING MARKET FOR PCR, BY REGION, 2021-2028 (USD MILLION)
• 9.4 DNA MICROARRAYS
  • 9.4.1 ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET
  • TABLE 38 DNA MICROARRAYS USED BY MARKET PLAYERS
  • TABLE 39 CARRIER SCREENING MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)
• 9.5 OTHER TECHNOLOGIES
  • TABLE 40 ADVANTAGES OF OTHER TECHNOLOGIES FOR CARRIER SCREENING
  • TABLE 41 CARRIER SCREENING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

10 CARRIER SCREENING MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 42 CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.2 HOSPITALS AND MEDICAL CENTERS
  • 10.2.1 RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT
  • TABLE 43 CARRIER SCREENING MARKET FOR HOSPITALS AND MEDICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET
  • TABLE 44 CARRIER SCREENING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
• 10.4 FERTILITY CLINICS
  • 10.4.1 INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET
  • TABLE 45 CARRIER SCREENING MARKET FOR FERTILITY CLINICS, BY REGION, 2021-2028 (USD MILLION)
• 10.5 OTHER END USERS
  • TABLE 46 CARRIER SCREENING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

11 CARRIER SCREENING MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 47 CARRIER SCREENING MARKET, BY REGION, 2021-2028 (USD MILLION)
• 11.2 NORTH AMERICA
  • FIGURE 32 NORTH AMERICA: CARRIER SCREENING MARKET SNAPSHOT
  • TABLE 48 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 51 NORTH AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • 11.2.2 US
    • 11.2.2.1 Increasing number of genetic diseases and rising healthcare expenditure to drive market
  • TABLE 55 US: KEY MACROINDICATORS
  • TABLE 56 US: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 57 US: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 58 US: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 59 US: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 60 US: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 61 US: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing government and non-government funding to drive market
  • TABLE 62 CANADA: KEY MACROINDICATORS
  • TABLE 63 CANADA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 64 CANADA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 65 CANADA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 66 CANADA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 67 CANADA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 68 CANADA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.3 EUROPE
  • TABLE 69 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
  • 11.3.1 EUROPE: RECESSION IMPACT
  • TABLE 70 EUROPE: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 71 EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 72 EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 73 EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 74 EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 75 EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 76 EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing number of government initiatives and healthcare expenditures to drive market
  • TABLE 77 GERMANY: KEY MACROINDICATORS
  • TABLE 78 GERMANY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 79 GERMANY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 80 GERMANY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 81 GERMANY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 82 GERMANY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 83 GERMANY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.3 UK
    • 11.3.3.1 Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market
  • TABLE 84 UK: KEY MACROINDICATORS
  • TABLE 85 UK: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 86 UK: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 87 UK: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 88 UK: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 89 UK: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 90 UK: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.4 FRANCE
    • 11.3.4.1 Better healthcare infrastructure and higher expenditure for life science research to drive market
  • TABLE 91 FRANCE: KEY MACROINDICATORS
  • TABLE 92 FRANCE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 93 FRANCE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 94 FRANCE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 95 FRANCE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 96 FRANCE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 97 FRANCE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.5 ITALY
    • 11.3.5.1 Growing prevalence of chronic diseases and rising number of hospitals to drive market
  • TABLE 98 ITALY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 99 ITALY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 100 ITALY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 101 ITALY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 102 ITALY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 103 ITALY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market
  • TABLE 104 SPAIN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 105 SPAIN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 106 SPAIN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 107 SPAIN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 108 SPAIN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 109 SPAIN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.7 REST OF EUROPE
  • TABLE 110 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
  • TABLE 111 REST OF EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 112 REST OF EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 113 REST OF EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 114 REST OF EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 115 REST OF EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 116 REST OF EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • FIGURE 33 ASIA PACIFIC: CARRIER SCREENING MARKET SNAPSHOT
  • TABLE 117 ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.2 INDIA
    • 11.4.2.1 Growing incidence of rare diseases and declining fertility rates to drive market
  • TABLE 123 INDIA: KEY MACROINDICATORS
  • TABLE 124 INDIA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 125 INDIA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 126 INDIA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 INDIA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 128 INDIA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 129 INDIA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.3 CHINA
    • 11.4.3.1 Rising focus on vaccine development and cancer research to drive market
  • TABLE 130 CHINA: KEY MACROINDICATORS
  • TABLE 131 CHINA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 132 CHINA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 133 CHINA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 134 CHINA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 135 CHINA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 136 CHINA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.4 JAPAN
    • 11.4.4.1 Rising geriatric population and growing government healthcare expenditure to drive market
  • TABLE 137 JAPAN: KEY MACROINDICATORS
  • TABLE 138 JAPAN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 139 JAPAN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 140 JAPAN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 JAPAN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 142 JAPAN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 143 JAPAN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.5 REST OF ASIA PACIFIC
  • TABLE 144 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 145 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 146 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.5 REST OF THE WORLD
  • 11.5.1 REST OF THE WORLD: RECESSION IMPACT
  • TABLE 150 REST OF THE WORLD: CARRIER SCREENING MARKET, BY PRODUCT & 2021-2028 (USD MILLION)
  • TABLE 151 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 152 REST OF THE WORLD: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 153 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 154 REST OF THE WORLD: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 155 REST OF THE WORLD: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.2 LATIN AMERICA
    • 11.5.2.1 Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market
  • TABLE 156 DEFINITION OF RARE DISEASES IN VARIOUS COUNTRIES
  • TABLE 157 LATIN AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 158 LATIN AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 159 LATIN AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 160 LATIN AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 161 LATIN AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 162 LATIN AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.3 MIDDLE EAST & AFRICA
  • TABLE 163 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3.1 GCC Countries
      • 11.5.3.1.1 Improved healthcare infrastructure and launch of genome projects to drive market
  • TABLE 169 GCC COUNTRIES: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET
• 12.3 MARKET SHARE ANALYSIS
  • TABLE 176 DEGREE OF COMPETITION: CARRIER SCREENING MARKET
• 12.4 REVENUE SHARE ANALYSIS
  • FIGURE 34 REVENUE SHARE ANALYSIS OF KEY PLAYERS
• 12.5 COMPANY EVALUATION MATRIX
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • FIGURE 35 COMPANY EVALUATION MATRIX, 2022
  • 12.5.5 COMPANY FOOTPRINT
  • TABLE 177 OVERALL COMPANY FOOTPRINT
  • TABLE 178 PRODUCT FOOTPRINT
  • TABLE 179 REGIONAL FOOTPRINT
• 12.6 START-UP/SME EVALUATION MATRIX
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • FIGURE 36 START-UP/SME EVALUATION MATRIX, 2022
  • 12.6.5 COMPETITIVE BENCHMARKING
  • TABLE 180 DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING MARKET
• 12.7 COMPETITIVE SCENARIOS AND TRENDS
  • 12.7.1 KEY DEALS
  • TABLE 181 KEY DEALS, JANUARY 2020-DECEMBER 2023

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
• (Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)**
• 13.1.1 NATERA, INC.
• TABLE 182 NATERA, INC.: COMPANY OVERVIEW
• FIGURE 37 NATERA, INC.: COMPANY SNAPSHOT (2022)
• 13.1.2 QUEST DIAGNOSTICS INCORPORATED
• TABLE 183 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
• FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022)
• 13.1.3 FULGENT GENETICS
• TABLE 184 FULGENT GENETICS: COMPANY OVERVIEW
• FIGURE 39 FULGENT GENETICS.: COMPANY SNAPSHOT (2022)
• 13.1.4 INVITAE CORPORATION
• TABLE 185 INVITAE CORPORATION: COMPANY OVERVIEW
• FIGURE 40 INVITAE CORPORATION.: COMPANY SNAPSHOT (2022)
• 13.1.5 EUROFINS SCIENTIFIC
• TABLE 186 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
• FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
• 13.1.6 OPKO HEALTH, INC.
• TABLE 187 OPKO HEALTH, INC.: COMPANY OVERVIEW
• FIGURE 42 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022)
• 13.1.7 THERMO FISHER SCIENTIFIC INC.
• TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
• 13.1.8 MYRIAD GENETICS, INC.
• TABLE 189 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
• FIGURE 44 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
• 13.1.9 ILLUMINA, INC.
• TABLE 190 ILLUMINA, INC.: COMPANY OVERVIEW
• FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
• 13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
• TABLE 191 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
• FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
• 13.1.11 CENTOGENE N.V.
• TABLE 192 CENTOGENE N.V.: COMPANY OVERVIEW
• FIGURE 47 CENTOGENE N.V.: COMPANY SNAPSHOT (2022)
• 13.1.12 DIASORIN S.P.A.
• TABLE 193 DIASORIN S.P.A.: COMPANY OVERVIEW
• FIGURE 48 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
• 13.1.13 BGI
• TABLE 194 BGI: COMPANY OVERVIEW
• 13.1.14 OTOGENETICS
• TABLE 195 OTOGENETICS: COMPANY OVERVIEW
• 13.1.15 GENETECH
• TABLE 196 GENETECH: COMPANY OVERVIEW
• 13.2 OTHER PLAYERS
  • 13.2.1 OXY-GEN LABORATORY LLC
  • TABLE 197 OXY-GEN LABORATORY LLC: COMPANY OVERVIEW
  • 13.2.2 MEDGENOME
  • TABLE 198 MEDGENOME: COMPANY OVERVIEW
  • 13.2.3 AMBRY GENETICS.
  • TABLE 199 AMBRY GENETICS: COMPANY OVERVIEW
  • 13.2.4 ASPER BIOGENE
  • TABLE 200 ASPER BIOGENE: COMPANY OVERVIEW
  • 13.2.5 LIFELABS GENETICS
  • TABLE 201 LIFELABS GENETICS: COMPANY OVERVIEW
  • 13.2.6 EASYDNA
  • TABLE 202 EASYDNA: COMPANY OVERVIEW
  • 13.2.7 LIFECELL
  • TABLE 203 LIFECELL: COMPANY OVERVIEW
  • 13.2.8 CNC PATH LAB
  • TABLE 204 CNC PATH LAB: COMPANY OVERVIEW
  • 13.2.9 SIGNATURE DIAGNOSTICS INC.
  • TABLE 205 SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW
  • 13.2.10 MITERA
  • TABLE 206 MITERA: COMPANY OVERVIEW
• *Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

관련자료